Igovomab Biosimilar - Research Grade

Human

MUC16

>1mg/ml

F(ab')2 - G1 - nd

CHO Cells

Sofituzumab Biosimilar - Research Grade (ICH5086), Abagovomab Biosimilar - Research Grade (ICH5321), Oregovomab Biosimilar - Research Grade (ICH5743)

https://www.imgt.org/mAb-DB/

ICH3002

Q8WXI7

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of igovomab, an anti-MUC16 (CA125) agent, supplied strictly for research use. It is not the clinical/diagnostic agent and is not intended for human or veterinary use. Built around the MUC16 target and provided in an F(ab')2 format, it lets laboratories study CA125/MUC16 recognition without an intact Fc region, which is useful when Fc-mediated effects would otherwise confound an assay. Typical research applications include use as a binding reagent, a positive or benchmarking control in target-engagement and ELISA/flow work, an isotype- and format-matched comparator during antibody or ADC development, and a tool for in-vitro neutralisation and epitope-competition studies. The material is offered at bulk milligram-to-gram scale with low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) options for sensitive cell-based and preclinical model work. Consistent lot-to-lot supply supports assay standardisation, screening campaigns, and reproducibility across a research programme. It carries no therapeutic claim. MUC16 (UniProt Q8WXI7), the gene product commonly measured clinically as the CA125 antigen, is an extremely large, heavily O-glycosylated transmembrane mucin. Its architecture includes a very long extracellular region containing numerous tandem repeats, a series of SEA domains, a single transmembrane pass, and a short cytoplasmic tail. The bulky, glycan-rich ectodomain forms part of the protective mucosal barrier at epithelial surfaces and can be proteolytically shed, releasing soluble CA125 into circulation, which underlies its widespread use as a serum marker. MUC16 is expressed by coelomic-derived epithelia and is frequently overexpressed by epithelial ovarian carcinomas and some other adenocarcinomas. Through its glycans and cytoplasmic interactions it is implicated in cell adhesion, lubrication, immune modulation, and signaling that can influence tumour-cell survival and metastasis, making it a longstanding focus for oncology diagnostics and targeted-therapy research.

Ovarian cancer-related tumor marker CA125, CA-125, Ovarian carcinoma antigen CA125, Mucin-16

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks